Here are the 8-K filings from SeaStar Medical Holding Corporation Warrant (ICUCW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow ICUCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUCW filings page.
SeaStar Medical Holding Corp said the FDA determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry fulfilled post-approval study requirements under the therapy’s original Humanitarian Device Exemption approval. SeaStar Medical said hospitals can now use the therapy without the research infrastructure required by the registry and that it will continue voluntary enrollment at participating centers.
Registry results presented at ASN Kidney Week 2026 reported 90-day survival of 65.1% among 43 QUELIMMUNE patients, versus 47.5% among 196 patients in clinically aligned Kids’ Inpatient Database cohorts (P = 0.043); the presentation also reported no device-related adverse events. QUELIMMUNE’s HDE approval was based on safety and probable benefit, and its effectiveness for this use has not been demonstrated.
SeaStar Medical Holding Corporation (ICU) completed the cash exercise of warrants covering 854,002 common shares at a reduced exercise price of $3.866 per share, generating approximately $3.3 million in gross proceeds before placement-agent fees and offering expenses. The closing occurred October 5, 2026. SeaStar intends to use net proceeds for general corporate purposes, which may include working capital and capital expenditures.
In connection with the exercise, holders received unregistered, immediately exercisable Series A and Series B warrants, each covering up to 854,002 shares at $3.616 per share. Series A warrants have a five-year term and Series B warrants an 18-month term, each measured from the effective date of the resale registration statement. SeaStar also issued its placement agent warrants for 59,780 shares at $4.8325 per share. The company agreed to file the resale registration statement within 30 calendar days after October 2, 2026, and to use commercially reasonable efforts to have it declared effective within 60 calendar days, or 90 calendar days in the case of an SEC full review.
SeaStar Medical Holding Corporation reported second quarter 2026 results with strong revenue growth but widening losses. Net revenue for the three months ended June 30, 2026 was $0.615 million, up from $0.338 million in 2025, an 82% increase driven by growing adoption of QUELIMMUNE pediatric AKI therapy. Gross margin remained high at 91% on cost of goods sold of $54 thousand.
Operating expenses rose significantly as the company invested in its pipeline and commercialization. Research and development expense increased to $2.52 million from $1.04 million, primarily from higher clinical trial and personnel costs, while general and administrative expense rose to $1.83 million from $1.03 million. Net loss for the quarter widened to $3.73 million, or $0.91 per share, compared with a net loss of $2.00 million, or $1.77 per share, with weighted-average shares rising to 4.08 million.
Cash was $6.96 million as of June 30, 2026, down from $11.98 million at December 31, 2025, after using $5.76 million in operating cash during the first half of 2026. The company highlighted business progress including adding three top-rated children’s hospitals to the QUELIMMUNE customer base, advancing enrollment in the 339-patient NEUTRALIZE-AKI pivotal adult AKI trial, and obtaining ICD-10-PCS codes to support standardized inpatient billing for its SCD therapies.
SeaStar Medical Holding Corporation approved cash and stock retention bonuses for executives Eric Schlorff and Kevin Chung under a 2026 Retention Bonus Program. Schlorff’s bonus totals $200,000 and Chung’s totals $140,000, each split into three equal installments.
Each one-third payment is scheduled for July 1, 2026, November 1, 2026, and March 1, 2027, subject to continued employment on each vesting date. Executives will also receive an additional amount equal to 25% of each payment in shares of common stock under the 2022 Omnibus Incentive Plan, based on the closing share price on each vesting date.
If an executive departs before a vesting date, remaining payments are forfeited, while a separation without cause provides a pro‑rated amount of the next payment. The company executed individual 2026 Retention Bonus Program Agreements with both executives, filed as exhibits to this report.
SeaStar Medical Holding Corporation filed an amended report describing a new separation and release agreement with Mr. Green. The agreement, entered into on June 10, 2026, provides a mutual resolution of issues surrounding a previously disputed not-for-cause termination.
Under this new agreement, SeaStar Medical has agreed to pay Mr. Green more than was disclosed in the earlier report signed on August 19, 2025. The filing indicates all claims related to that dispute are being released as part of the mutual resolution.
SeaStar Medical Holding Corporation reported results from its annual stockholder meeting held on June 17, 2026. Stockholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of authorized shares of common stock available under the plan from 207,046 shares to 896,546 shares, supporting future equity-based compensation.
Stockholders also elected John Neuman as a Class I director to serve until the 2029 annual meeting. They ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved a proposal allowing adjournment or postponement of the meeting if additional proxy solicitation were needed.
SeaStar Medical reported first quarter 2026 results showing early commercial traction but continued losses. Net revenue reached $0.5 million, up from $0.3 million a year earlier, driven by sales of its QUELIMMUNE pediatric AKI therapy and a 69% year-over-year revenue increase.
The company added seven top-rated children’s hospitals to its QUELIMMUNE customer base and advanced enrollment in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury. SeaStar recorded a net loss of $3.5 million, slightly improved from a $3.8 million loss in the prior-year quarter.
Research and development expenses were $2.3 million and general and administrative expenses were $1.7 million, both roughly flat versus last year. Cash was $9.3 million as of March 31, 2026, down from $12.0 million at year-end, reflecting ongoing operating cash use as the company invests in commercialization and its adult AKI trial.
SeaStar Medical Holding Corporation reports that a previously filed federal securities class action against the company and certain executives has been dismissed with prejudice. The lawsuit, filed in 2024, had alleged misstatements or omissions related to the company’s business, operations and a prior financial restatement.
After the parties submitted a stipulation of dismissal on April 21, 2026, the United States District Court for the District of Colorado ordered on April 27, 2026 that the case be dismissed with prejudice. This ruling closes the putative class action without the option for the same claims to be refiled.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.